长春高新,000661,收入构成,报告日期,2020-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中成药,26460,6907,19553,73.9%,5.87% 基因工程/生物类药品,312442,21894,290547,92.99%,87.19% 服务业,1817,702,1115,61.35%,0.33% 房地产,50945,28922,22023,43.23%,6.61% 长春高新,000661,收入构成,报告日期,2019-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务业,1429,335,1094,76.55%,0.17% 基因工程/生物类药品,582276,41473,540803,92.88%,86.09% 房地产,95678,53339,42340,44.25%,6.74% 中成药,57987,14025,43962,75.81%,7% 长春高新,000661,收入构成,报告日期,2019-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中成药,29119,7012,22107,75.92%,7.81% 生物制药,254710,19000,235710,92.54%,83.26% 服务业,1420,605,815,57.38%,0.29% 房地产,53906,29432,24474,45.4%,8.64% 长春高新,000661,收入构成,报告日期,2018-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 基因工程药品\生物类药品,422276,33397,388878,92.09%,85.01% 服务业,1930,830,1101,57.02%,0.24% 中成药,52755,12135,40620,77%,8.88% 房地产,60539,33713,26826,44.31%,5.86% 长春高新,000661,收入构成,报告日期,2018-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 房地产,39116,21836,17280,44.18%,7.48% 中成药,25613,5811,19802,77.31%,8.57% 生物制药,208511,15632,192879,92.5%,83.47% 服务业,1684,577,1106,65.71%,0.48% 长春高新,000661,收入构成,报告日期,2017-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务业,3254,1920,1334,40.99%,0.4% 房地产,61621,34921,26700,43.33%,7.94% 中成药,65228,14113,51115,78.36%,15.21% 基因工程药品\生物类药品,280123,23117,257006,91.75%,76.45% 长春高新,000661,收入构成,报告日期,2017-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务业,1600,639,962,60.09%,0.69% 生物制药,124805,11609,113196,90.7%,81.08% 房地产,3008,1632,1377,45.76%,0.99% 中成药,30593,6517,24076,78.7%,17.25% 长春高新,000661,收入构成,报告日期,2016-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务业,2715,1315,1400,51.58%,0.61% 中成药,59340,12751,46589,78.51%,20.25% 基因生物制药,172518,16594,155924,90.38%,67.76% 房地产,55171,28967,26204,47.5%,11.39% 长春高新,000661,收入构成,报告日期,2016-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务业,1251,360,892,71.26%,0.87% 中成药,27384,5772,21612,78.92%,21.01% 生物制药,76029,8022,68007,89.45%,66.11% 房地产,22892,10536,12356,53.98%,12.01% 长春高新,000661,收入构成,报告日期,2015-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务业,2341,1920,420,17.95%,0.22% 中成药,56817,12487,44330,78.02%,23.56% 基因生物制药,131927,14639,117288,88.9%,62.34% 房地产,49124,23028,26096,53.12%,13.87% 长春高新,000661,收入构成,报告日期,2015-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务业,1107,595,512,46.25%,0.6% 房地产,20355,9296,11059,54.33%,13.07% 中成药,25273,5716,19557,77.38%,23.11% 基因工程药品\生物类药品,60689,7189,53500,88.15%,63.22% 长春高新,000661,收入构成,报告日期,2014-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务业,2327,1134,1193,51.28%,0.69% 中成药,59780,13303,46477,77.75%,26.84% 生物制药,116340,11909,104431,89.76%,60.31% 房地产,47784,26734,21050,44.05%,12.16% 长春高新,000661,收入构成,报告日期,2014-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务业,1537,731,807,52.47%,1.09% 中成药,27239,5872,21367,78.44%,28.96% 基因工程药品生物类药品,54639,4966,49672,90.91%,67.33% 房地产,4190,2264,1925,45.96%,2.61% 长春高新,000661,收入构成,报告日期,2013-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务业,2104,1052,1051,49.98%,0.63% 房地产,33275,14010,19265,57.9%,11.58% 中成药,53054,9342,43712,82.39%,26.27% 生物制药,116437,14050,102387,87.93%,61.53% 长春高新,000661,收入构成,报告日期,2013-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务业,1702,871,831,48.81%,1.06% 中成药,26131,4645,21486,82.22%,27.5% 基因工程药品生物类药品,53347,6019,47327,88.72%,60.58% 房地产,15254,6772,8482,55.6%,10.86% 长春高新,000661,收入构成,报告日期,2012-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务业,2304,1103,1200,52.1%,0.83% 中成药,46830,9039,37791,80.7%,26.18% 基因工程药品生物类药品,97372,9236,88136,90.51%,61.07% 房地产,29614,12412,17202,58.09%,11.92% 长春高新,000661,收入构成,报告日期,2012-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务业,701,586,114,16.33%,0.17% 基因工程药品生物类药品,46387,4495,41892,90.31%,62.86% 房地产,13810,6682,7128,51.62%,10.7% 中成药,21651,4147,17504,80.85%,26.27% 长春高新,000661,收入构成,报告日期,2011-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中成药,38874,8317,30557,78.6%,28.84% 基因工程药品\生物类药品,70581,7194,63386,89.81%,59.83% 房地产,17803,5797,12006,67.44%,11.33% 长春高新,000661,收入构成,报告日期,2011-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中成药,18581,2269,16312,87.79%,37% 生物制药,31661,3882,27778,87.74%,63% 长春高新,000661,收入构成,报告日期,2010-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务业,2375,850,1525,64.19%,1.72% 房地产,26268,13605,12663,48.21%,14.27% 制药业,87953,13416,74537,84.75%,84.01% 长春高新,000661,收入构成,报告日期,2010-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中成药,15780,2981,12799,81.11%,37.25% 生物制药,24856,3292,21564,86.76%,62.75% 长春高新,000661,收入构成,报告日期,2009-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中成药,30206,7988,22218,73.55%,29.99% 基因工程药品,45960,4153,41807,90.96%,56.42% 房地产,23899,13829,10070,42.14%,13.59% 长春高新,000661,收入构成,报告日期,2009-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中成药,15156,4084,11073,73.06%,39.21% 生物制药,18479,1310,17169,92.91%,60.79% 长春高新,000661,收入构成,报告日期,2008-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中成药,26112,8838,17274,66.15%,32.75% 基因工程药品,27267,1850,25417,93.22%,48.19% 房地产,25593,15539,10054,39.28%,19.06% 长春高新,000661,收入构成,报告日期,2008-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中成药,12909,4260,8649,67%,53.36% 生物制药,8313,754,7559,90.93%,46.64% 长春高新,000661,收入构成,报告日期,2007-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 中成药,19781,7200,12581,63.6%,31.31% 基因工程药品,21173,1579,19594,92.54%,48.76% 房地产,22784,14776,8008,35.15%,19.93% 长春高新,000661,收入构成,报告日期,2007-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 血栓心脉宁,1633,468,1166,71.37%,10.32% 基因重组人生长素,10824,688,10136,93.64%,89.68% 长春高新,000661,收入构成,报告日期,2006-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 血栓心脉宁,4785,1797,2988,62.45%,13.34% 基因重组人生长素,16740,1110,15630,93.37%,69.8% 房地产,21694,17921,3773,17.39%,16.85% 长春高新,000661,收入构成,报告日期,2006-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 血栓心脉宁,3538,1287,2251,63.62%,15.45% 基因重组人生长素,13268,947,12321,92.86%,84.55% 长春高新,000661,收入构成,报告日期,2006-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 血栓心脉宁,2377,861,1516,63.78%,16.58% 基因重组人生长素,8305,678,7627,91.84%,83.42% 长春高新,000661,收入构成,报告日期,2006-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 血栓心脉宁,1158,433,725,62.61%,17.12% 基因重组人生长素,3875,364,3511,90.6%,82.88% 长春高新,000661,收入构成,报告日期,2005-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 血栓心脉宁,5239,1627,3612,68.94%,23.37% 基因重组人生长素,13157,1317,11841,89.99%,76.63% 长春高新,000661,收入构成,报告日期,2005-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 血栓心脉宁,3740,1109,2631,70.35%,22.18% 生长素,10284,1055,9229,89.74%,77.82% 长春高新,000661,收入构成,报告日期,2005-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 血栓心脉宁,2496,724,1772,70.99%,32.81% 基因重组人生长素,3976,348,3628,91.25%,67.19% 长春高新,000661,收入构成,报告日期,2005-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 血栓心脉宁,943,266,677,71.79%,19.18% 生长素,3297,445,2852,86.5%,80.82% 长春高新,000661,收入构成,报告日期,2004-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 血栓心脉宁,5591,1475,4116,73.61%,32.16% 基因重组人生长素,9925,1242,8683,87.49%,67.84% 长春高新,000661,收入构成,报告日期,2004-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 血栓心脉宁,3921,1022,2899,73.94%,28.57% 生长素,8182,935,7247,88.57%,71.43% 长春高新,000661,收入构成,报告日期,2004-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 冠脉宁,947,184,763,80.57%,11.06% 血栓心脉宁,2429,637,1792,73.78%,25.97% 基因重组人生长素,4920,575,4345,88.31%,62.97% 长春高新,000661,收入构成,报告日期,2003-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 血栓心脉宁,4681,1001,3680,78.61%,32.34% 基因重组人生长素,4724,686,4038,85.49%,35.48% 人用狂犬病纯化疫苗(VERO细胞),6358,2696,3662,57.6%,32.18% 长春高新,000661,收入构成,报告日期,2003-09-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 血栓心脉宁,2884,598,2286,79.26%,27.49% 基因重组人生长素,3402,530,2872,84.42%,34.54% 人用精致狂犬疫苗(Vero细胞),5075,1917,3158,62.23%,37.97% 长春高新,000661,收入构成,报告日期,2003-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 甲型肝炎减毒活疫苗,1656,570,1086,65.58%,16.41% 血栓心脉宁,1618,370,1248,77.13%,18.85% 基因重组人生长素,2777,464,2313,83.29%,34.94% 人用狂犬病纯化疫苗Vero(细胞),2863,891,1972,68.88%,29.79% 长春高新,000661,收入构成,报告日期,2003-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 Vero狂犬,1719,552,1167,67.91%,100% 长春高新,000661,收入构成,报告日期,2002-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 人用狂犬病纯化疫苗(VERO细胞),11429,4173,7256,63.49%,56.18% 血栓心脉宁,7308,1648,5660,77.45%,43.82% 长春高新,000661,收入构成,报告日期,2002-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 服务业,1831,459,1372,74.94%,9.07% 制药,18508,4755,13754,74.31%,90.93% 长春高新,000661,收入构成,报告日期,2001-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 房地产销售,6100,4825,1275,20.9%,12.83% 人用狂犬病纯化疫苗(VERO细胞),4173,1206,2967,71.1%,29.86% 血栓心脉宁,7566,1872,5694,75.26%,57.31%